Comparison of the hospital anxiety and depression scale and the center for epidemiological studies depression scale for detecting depression in women with breast or gynecologic cancer
- PMID: 24200105
- DOI: 10.1016/j.genhosppsych.2013.08.010
Comparison of the hospital anxiety and depression scale and the center for epidemiological studies depression scale for detecting depression in women with breast or gynecologic cancer
Abstract
Objective: Depression is common in cancer patients but frequently undetected. Consensus regarding validity and optimal thresholds of screening measures is lacking. We investigated the validity of the Hospital Anxiety and Depression Scale (HADS-D) and Center for Epidemiological Studies Depression Scale (CES-D) relative to a referent diagnostic standard in women with breast or gynecologic cancer.
Method: Participants were 100 patients who completed the CES-D and HADS-D within a larger study. The Mini International Neuropsychiatric Interview was the criterion standard. Sensitivity, specificity, predictive values and likelihood ratios for various thresholds were calculated using receiver operating characteristics. Participants were assigned to two diagnostic groups: 'major depressive disorder' or 'any depressive disorder'.
Results: Separate analyses were conducted whereby participants found to be receiving depression/anxiety treatment at the time of validation (n=28) were excluded. Both measures had good internal consistency and criterion validity. There were no statistical differences in global accuracy between the measures for detecting either group. For optimal sensitivity and specificity in both groups, generally recommended thresholds were lowered for the HADS-D. For the CES-D, the threshold was lowered for 'any depressive disorder' and raised for 'major depressive disorder'. Negative predictive values associated with our recommended cutoffs were excellent, but positive predictive values were poor.
Conclusions: The HADS-D and CES-D have acceptable properties and are equivalent for detecting depression in this population. Depending on the purpose of screening, the CES-D may be more suitable for identifying major depression. Threshold choice may have serious implications for screening program effectiveness, and the use of generally recommended thresholds should be cautious.
Keywords: Cancer; Depression; Oncology; Screening; Validity.
© 2014.
Similar articles
-
Validity of the Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients with coronary artery disease.Gen Hosp Psychiatry. 2007 Sep-Oct;29(5):417-24. doi: 10.1016/j.genhosppsych.2007.06.005. Gen Hosp Psychiatry. 2007. PMID: 17888808
-
[The accuracy of HADS and GHQ-12 in detecting psychiatric morbidity in breast cancer patients].Turk Psikiyatri Derg. 2010 Spring;21(1):49-59. Turk Psikiyatri Derg. 2010. PMID: 20204904 Turkish.
-
Diagnostic accuracy of self-rating scales for screening of depression in coronary artery disease patients.J Psychosom Res. 2012 Jan;72(1):22-5. doi: 10.1016/j.jpsychores.2011.10.006. Epub 2011 Nov 30. J Psychosom Res. 2012. PMID: 22200518
-
The utility of the CES-D as a depression screening measure among low-income women attending primary care clinics. The Center for Epidemiologic Studies-Depression.Int J Psychiatry Med. 2001;31(1):25-40. doi: 10.2190/FUFR-PK9F-6U10-JXRK. Int J Psychiatry Med. 2001. PMID: 11529389 Review.
-
Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis.BMJ. 2021 May 10;373:n972. doi: 10.1136/bmj.n972. BMJ. 2021. PMID: 33972268 Free PMC article.
Cited by
-
The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women's response to integrative breast cancer treatment.BMC Cancer. 2021 Jun 23;21(1):724. doi: 10.1186/s12885-021-08468-2. BMC Cancer. 2021. PMID: 34162339 Free PMC article.
-
Risk of Bias from Inclusion of Currently Diagnosed or Treated Patients in Studies of Depression Screening Tool Accuracy: A Cross-Sectional Analysis of Recently Published Primary Studies and Meta-Analyses.PLoS One. 2016 Feb 26;11(2):e0150067. doi: 10.1371/journal.pone.0150067. eCollection 2016. PLoS One. 2016. PMID: 26919313 Free PMC article.
-
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23. Oncologist. 2016. PMID: 27009936 Free PMC article. Clinical Trial.
-
The efficacy of Guolin-Qigong on the body-mind health of Chinese women with breast cancer: a randomized controlled trial.Qual Life Res. 2017 Sep;26(9):2321-2331. doi: 10.1007/s11136-017-1576-7. Epub 2017 Apr 18. Qual Life Res. 2017. Retraction in: Qual Life Res. 2021 Mar;30(3):955. doi: 10.1007/s11136-020-02672-6. PMID: 28421384 Retracted. Clinical Trial.
-
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.Breast Cancer Res Treat. 2017 Jul;164(2):411-419. doi: 10.1007/s10549-017-4260-2. Epub 2017 Apr 27. Breast Cancer Res Treat. 2017. PMID: 28451964 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical